Drug Trial Radar · NCT07277582
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Mar 7, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Thryv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2) and Long QT Syndrome Type 3 (LQTS 3). The study will also learn about the safety and tolerability of THRV-1268 at different doses. The main questions this study aims to answer are: Does THRV-1268 reduce the QTc interval (a measure of the heart's electrical recovery time)? What side effects or medical problems occur when participants take THRV-1268? Which dose of THRV-1268 works best and is safest? Participants will: Complete a 3-week observation period with ECG and Holter monitoring to establish baseline QTc measurements Take THRV-1268 twice daily at two dose levels for 6 weeks (Part A) or be randomly assigned to a dose group for 6 weeks (Part B - cohort 1) Have clinic visits and tests to monitor safety and changes in their heart rhythm May continue taking THRV-1268 for up to 1 year for ongoing safety and efficacy evaluation Researchers will compare changes in QTc over time and evaluate side effects to determine whether THRV-1268 can help reduce the risk of abnormal heart rhythms and sudden cardiac events in people with LQTS 2 and LQTS 3.
Conditions
- Long QT Syndrome (LQTS) 2
Interventions
baseline lead-inOther
Participants will undergo a 3 weeks run-in baseline
THRV-1268Drug
THRV-1268 50 mg bid (total daily 100 mg) for 6 weeks
THRV-1268Drug
THRV-1268 100 mg bid (total daily 200 mg) for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To evaluate the effect of oral THRV-1268 on QTcF interval by AUC method in participants with LQTS 2Time frame: Day 42 and Day 84
- Part A: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])Time frame: up to 52 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Honor Health Research and Innovation Institute
Scottsdale, Arizona · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Illinois Chicago
Chicago, Illinois · Recruiting
Heart Center Clinical Research Program | MGH
Boston, Massachusetts · Recruiting
University of Michigan
Arbor, Michigan · Not yet recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
NYU Langone Health
New York, New York · Not yet recruiting
Wilmington Health
Wilmington, North Carolina · Recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.